Latest / Breaking News To Trading Moves
The Fenebrutinib Breakthrough: Shaping the Future of MS Therapeutics
Roche fenebrutinib hits phase 3 goal in primary progressive MS
What happened
Roche said its experimental multiple sclerosis drug fenebrutinib met the main objective in a Phase III trial in primary progressive multiple sclerosis (PPMS). In the study, fenebrutinib reduced the risk of disability progression by 12% versus Roche’s current PPMS standard, Ocrevus, with separation showing after 24 weeks. Roche said it plans to pursue approval after additional Phase III data from an ongoing relapsing MS study expected in the 1st half of 2026.
Why markets care
PPMS has limited treatment options and…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.